Paradigm (ASX:PAR) share price rises on partnership news

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the rise today following a partnership agreement. Here are the details.

| More on:
hand on touch screen lit up by a share price chart moving higher

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is on the rise this morning following a partnership agreement. At the time of writing, the biopharmaceutical company's shares are up 1.92% to $2.66.

What did Paradigm announce?

Paradigm shares are on the move today after updating the ASX with a positive announcement.

According to this morning's release, Paradigm advised that it has entered into a collaboration agreement with bene pharmChem (Bene). This follows a recently updated exclusive licence and supply deal between both parties in September last year.

Furthermore, the new agreement will seek to co-fund new R&D projects to unlock the potential benefits of Pentosan Polysulfate Sodium (PPS). Paradigm and Bene have also committed to work together on new intellectual (IP) property ownership to protect future innovations. This will be managed by the newly created, Joint Steering Committee. The purpose of the committee is to identify new projects, intended outcomes, and attribute IP ownership.

PPS, an injectable solution, aims to treat musculoskeletal disorders caused by injury, inflammation, aging, degenerative disease, infection or genetic predisposition. The semi-synthetic drug is packaged as Zilosul, and has shown improvements in pain reduction, joint function, and the prevention of cartilage damaging joints.

Additionally, Paradigm highlighted the importance of its longstanding relationship with Bene, the only approved manufacturer/supplier of PPS in the United States. While the new agreement establishes jointly funded activities, Paradigm will retain exclusive commercial rights to all information and developments.

Management commentary

Bene pharmaChem co-managing director Dr. Harald Benend commented on the upcoming trials for PPS:

Bene is excited by the imminent commencement of the phase 3 program for osteoarthritis and will be assisting Paradigm in any way possible to achieve the goal of successful registration and commercialisation of Zilosul for OA (osteoarthrosis).

Paradigm CEO and acting chair Paul Rennie also added:

We are eagerly awaiting the commencement of the pivotal phase 3 program for osteoarthritis; the market is eager for a safe and effective non-opioid therapy to relieve the burden of pain in osteoarthritis, PPS is showing great promise to meet this need.

About the Paradigm share price

The Paradigm share price has gained over 60% in the past 12 months, and is slightly up 2% year-to-date. The company's share price also reached a 52-week high of $3.88 in late June of 2020.

Based on the current share price, Paradigm has a market capitalisation of around $589 million, with 225.8 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the local market today.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Share Gainers

These were the best-performing ASX All Ords shares in May

These shares caught the eye last month. What was getting investors excited?

Read more »

A man and a woman sitting in a technology-related work environment high five each other while the man wears headphones around his neck and the woman sits in front of a laptop.
Share Market News

Strong gains for Wisetech, TechnologyOne, and Catapult amid ASX 200 tech sector lead

ASX technology shares led the market with a 3.85% increase while the ASX 200 lifted 0.88% last week.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Warren Buffett
Share Market News

Could these Australian fund managers be the next Warren Buffett?

Buffett is widely regarded the world's most successful investor.

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX 200 shares could rise 40%+

Big returns could be on offer from these shares according to analysts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Analysts say these ASX shares are top buys in June

Brokers are urging investors to buy these shares. Let's find out why.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a high note this Friday.

Read more »